Churchill Capital Corp III (CCXX) announced this afternoon that its shareholders had approved its business combination with healthcare data analytics-provider MultiPlan.
About 93% of shareholders representing about 76% of Churchill III’s total outstanding shares voted in favor of the transaction at a special meeting held earlier today.
The two parties expect to close the $11 billion business combination tomorrow and the newly combined entity is expected to begin trading on the NYSE under the symbol “MPLN” Friday, October 9.
Churchill III announced October 6 that as of its redemption deadline it had over $1 billion remaining in its $1.1 billion trust. Much of this was secured in advance as holders of 28,979,500 shares had already agreed not to redeem and owners of 41% of Chruchill III’s total outstanding shares had agreed to vote in favor of the agreement.
The SPAC was required to maintain a minimum of $2.7 billion available as a condition to closing the deal, and it appears to have locked up more than enough in advance with $3.6 billion in capital available at closing.
At the SPAC of Dawn (UPDATED) It was a slow start to the day after the Christmas holiday, especially because the SEC was “experiencing technical difficulties” this morning. That makes for a slow news day. Other than that, we hope everyone had a great holiday and is easing back into the work flow. Deals and...
Aimei Health Technology II Co., Ltd (NASDAQ:AHJKU) has filed for a $60 million SPAC ostensibly to pair up with a small cap biotech or medical device target, but its team’s experience both in SPACs and beyond suggest the vehicle will be open to a broad set of potential targets. It is the first SPAC to...
At the SPAC of Dawn The markets got to open one stocking early yesterday, but it was mostly coal as it showed durable goods orders had declined by more than twice as much as expected to -1.1% in November. It wasn’t all signs of naughtiness, however. Amid the numbers that came public one day earlier...
Copley Acquisition Corp has filed to raise a $150 million SPAC to hunt for a technology or lifestyle target in either the Asia Pacific or North America regions. The new S-1 also advances underwriter Clear Street in the league tables as it has backed two of the three latest SPACs to file in December, and...
Translational Development Acquisition Corp. (NASDAQ: TDACU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “TDACU”, Monday, December 23, 2024. The new SPAC intends to take a generalist approach in searching for a business combination, but intend to focus on industries that...